AVANTOR INC (AVTR)

US05352A1007 - Common Stock

21.21  +0.19 (+0.9%)

After market: 21.21 0 (0%)

Fundamental Rating

4

Overall AVTR gets a fundamental rating of 4 out of 10. We evaluated AVTR against 56 industry peers in the Life Sciences Tools & Services industry. AVTR has a medium profitability rating, but doesn't score so well on its financial health evaluation. AVTR is not valued too expensively and it also shows a decent growth rate.



6

1. Profitability

1.1 Basic Checks

AVTR had positive earnings in the past year.
AVTR had a positive operating cash flow in the past year.
AVTR had positive earnings in 4 of the past 5 years.
Each year in the past 5 years AVTR had a positive operating cash flow.

1.2 Ratios

With a decent Return On Assets value of 2.41%, AVTR is doing good in the industry, outperforming 71.43% of the companies in the same industry.
AVTR has a Return On Equity of 5.58%. This is in the better half of the industry: AVTR outperforms 75.00% of its industry peers.
AVTR's Return On Invested Capital of 4.46% is fine compared to the rest of the industry. AVTR outperforms 71.43% of its industry peers.
AVTR had an Average Return On Invested Capital over the past 3 years of 6.66%. This is below the industry average of 9.98%.
Industry RankSector Rank
ROA 2.41%
ROE 5.58%
ROIC 4.46%
ROA(3y)3.68%
ROA(5y)1.63%
ROE(3y)10.62%
ROE(5y)4.04%
ROIC(3y)6.66%
ROIC(5y)6.37%

1.3 Margins

AVTR has a better Profit Margin (4.54%) than 69.64% of its industry peers.
AVTR's Profit Margin has improved in the last couple of years.
With a decent Operating Margin value of 9.24%, AVTR is doing good in the industry, outperforming 69.64% of the companies in the same industry.
AVTR's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 33.53%, AVTR is doing worse than 66.07% of the companies in the same industry.
AVTR's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 9.24%
PM (TTM) 4.54%
GM 33.53%
OM growth 3Y4.11%
OM growth 5Y8.45%
PM growth 3Y78.28%
PM growth 5YN/A
GM growth 3Y1.4%
GM growth 5Y1.8%

3

2. Health

2.1 Basic Checks

AVTR has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
AVTR has more shares outstanding than it did 1 year ago.
AVTR has more shares outstanding than it did 5 years ago.
AVTR has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 2.15 indicates that AVTR is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of AVTR (2.15) is comparable to the rest of the industry.
AVTR has a debt to FCF ratio of 6.59. This is a slightly negative value and a sign of low solvency as AVTR would need 6.59 years to pay back of all of its debts.
The Debt to FCF ratio of AVTR (6.59) is better than 62.50% of its industry peers.
AVTR has a Debt/Equity ratio of 0.84. This is a neutral value indicating AVTR is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.84, AVTR is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 6.59
Altman-Z 2.15
ROIC/WACC0.4
WACC11.05%

2.3 Liquidity

AVTR has a Current Ratio of 1.54. This is a normal value and indicates that AVTR is financially healthy and should not expect problems in meeting its short term obligations.
AVTR's Current ratio of 1.54 is on the low side compared to the rest of the industry. AVTR is outperformed by 73.21% of its industry peers.
AVTR has a Quick Ratio of 1.06. This is a normal value and indicates that AVTR is financially healthy and should not expect problems in meeting its short term obligations.
AVTR's Quick ratio of 1.06 is on the low side compared to the rest of the industry. AVTR is outperformed by 76.79% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.06

4

3. Growth

3.1 Past

The earnings per share for AVTR have decreased strongly by -14.04% in the last year.
The Earnings Per Share has been growing slightly by 6.33% on average over the past years.
Looking at the last year, AVTR shows a decrease in Revenue. The Revenue has decreased by -3.12% in the last year.
Measured over the past years, AVTR shows a small growth in Revenue. The Revenue has been growing by 3.51% on average per year.
EPS 1Y (TTM)-14.04%
EPS 3Y6.33%
EPS 5YN/A
EPS Q2Q%4%
Revenue 1Y (TTM)-3.12%
Revenue growth 3Y2.91%
Revenue growth 5Y3.51%
Sales Q2Q%-0.34%

3.2 Future

AVTR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.68% yearly.
AVTR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.86% yearly.
EPS Next Y-6.37%
EPS Next 2Y3.49%
EPS Next 3Y7.22%
EPS Next 5Y9.68%
Revenue Next Year-1.89%
Revenue Next 2Y-0.35%
Revenue Next 3Y1.43%
Revenue Next 5Y3.86%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

5

4. Valuation

4.1 Price/Earnings Ratio

AVTR is valuated rather expensively with a Price/Earnings ratio of 21.64.
Based on the Price/Earnings ratio, AVTR is valued cheaply inside the industry as 91.07% of the companies are valued more expensively.
AVTR's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.73.
With a Price/Forward Earnings ratio of 18.51, AVTR is valued on the expensive side.
87.50% of the companies in the same industry are more expensive than AVTR, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of AVTR to the average of the S&P500 Index (22.83), we can say AVTR is valued inline with the index average.
Industry RankSector Rank
PE 21.64
Fwd PE 18.51

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AVTR is valued cheaper than 91.07% of the companies in the same industry.
92.86% of the companies in the same industry are more expensive than AVTR, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 19.32
EV/EBITDA 18.42

4.3 Compensation for Growth

The decent profitability rating of AVTR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.49%
EPS Next 3Y7.22%

0

5. Dividend

5.1 Amount

No dividends for AVTR!.
Industry RankSector Rank
Dividend Yield N/A

AVANTOR INC

NYSE:AVTR (12/20/2024, 8:04:00 PM)

After market: 21.21 0 (0%)

21.21

+0.19 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-25 2024-10-25/bmo
Earnings (Next)02-12 2025-02-12/amc
Inst Owners95.7%
Inst Owner Change4.45%
Ins Owners1.2%
Ins Owner Change-0.43%
Market Cap14.44B
Analysts78
Price Target27.12 (27.86%)
Short Float %4.09%
Short Ratio4.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.92%
Min EPS beat(2)0.56%
Max EPS beat(2)5.29%
EPS beat(4)4
Avg EPS beat(4)5.6%
Min EPS beat(4)0.56%
Max EPS beat(4)10.08%
EPS beat(8)5
Avg EPS beat(8)2.01%
EPS beat(12)8
Avg EPS beat(12)2.13%
EPS beat(16)12
Avg EPS beat(16)4.96%
Revenue beat(2)0
Avg Revenue beat(2)-2.28%
Min Revenue beat(2)-2.59%
Max Revenue beat(2)-1.97%
Revenue beat(4)0
Avg Revenue beat(4)-1.81%
Min Revenue beat(4)-2.59%
Max Revenue beat(4)-0.59%
Revenue beat(8)0
Avg Revenue beat(8)-2.07%
Revenue beat(12)0
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-1.02%
PT rev (1m)-4.58%
PT rev (3m)-3.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.86%
EPS NY rev (1m)-0.13%
EPS NY rev (3m)-2.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.36%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)-1.46%
Valuation
Industry RankSector Rank
PE 21.64
Fwd PE 18.51
P/S 2.12
P/FCF 19.32
P/OCF 15.71
P/B 2.6
P/tB N/A
EV/EBITDA 18.42
EPS(TTM)0.98
EY4.62%
EPS(NY)1.15
Fwd EY5.4%
FCF(TTM)1.1
FCFY5.18%
OCF(TTM)1.35
OCFY6.37%
SpS10.02
BVpS8.16
TBVpS-5.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.41%
ROE 5.58%
ROCE 5.62%
ROIC 4.46%
ROICexc 4.58%
ROICexgc 28.89%
OM 9.24%
PM (TTM) 4.54%
GM 33.53%
FCFM 10.96%
ROA(3y)3.68%
ROA(5y)1.63%
ROE(3y)10.62%
ROE(5y)4.04%
ROIC(3y)6.66%
ROIC(5y)6.37%
ROICexc(3y)6.84%
ROICexc(5y)6.54%
ROICexgc(3y)47.27%
ROICexgc(5y)42.15%
ROCE(3y)8.38%
ROCE(5y)8.01%
ROICexcg growth 3Y1.28%
ROICexcg growth 5Y5.6%
ROICexc growth 3Y-2.83%
ROICexc growth 5Y6.5%
OM growth 3Y4.11%
OM growth 5Y8.45%
PM growth 3Y78.28%
PM growth 5YN/A
GM growth 3Y1.4%
GM growth 5Y1.8%
F-Score5
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 6.59
Debt/EBITDA 4.53
Cap/Depr 42.42%
Cap/Sales 2.52%
Interest Coverage 2.72
Cash Conversion 88.78%
Profit Quality 241.34%
Current Ratio 1.54
Quick Ratio 1.06
Altman-Z 2.15
F-Score5
WACC11.05%
ROIC/WACC0.4
Cap/Depr(3y)32.86%
Cap/Depr(5y)25.42%
Cap/Sales(3y)1.79%
Cap/Sales(5y)1.44%
Profit Quality(3y)166.14%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.04%
EPS 3Y6.33%
EPS 5YN/A
EPS Q2Q%4%
EPS Next Y-6.37%
EPS Next 2Y3.49%
EPS Next 3Y7.22%
EPS Next 5Y9.68%
Revenue 1Y (TTM)-3.12%
Revenue growth 3Y2.91%
Revenue growth 5Y3.51%
Sales Q2Q%-0.34%
Revenue Next Year-1.89%
Revenue Next 2Y-0.35%
Revenue Next 3Y1.43%
Revenue Next 5Y3.86%
EBIT growth 1Y-31.94%
EBIT growth 3Y7.14%
EBIT growth 5Y12.26%
EBIT Next Year1.16%
EBIT Next 3Y5.69%
EBIT Next 5Y7.4%
FCF growth 1Y-6.51%
FCF growth 3Y-5.89%
FCF growth 5Y34.76%
OCF growth 1Y-2.12%
OCF growth 3Y-2.19%
OCF growth 5Y34.12%